Click for article
The National Institute for Health and Care Excellence (NICE), in its final draft guidance issued this week, has recommended ixekizumab, an antibody that inhibits interleukin-17A, as an option for treating adults with severe plaque psoriasis that doesn’t respond to standard therapies.
Advertisements
0 Responses to “NICE recommends ixekizumab for persistent severe plaque psoriasis”